JMJenna Moore

Jenna Moore

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Jenna Moore has a total of 9 co-authors. Here are the top co-authors by number of shared publications:

  • Alexander Y. Kim

    Department of Genetic Medicine, Johns Hopkins School of Medicine, Baltimore, MD

    1 shared publication
  • Cèlia Rodríguez-Borjabad

    Vascular Medicine and Metabolism Unit, Research Unit on Lipids and Atherosclerosis, Sant Joan University Hospital, Universitat Rovira i Virgili, IISPV, 43201 Reus, Spain

    1 shared publication
  • Fiona J. White

    Central Manchester University Hospitals NHS Foundation Trust, Manchester, UK

    1 shared publication
  • Florian Abel

    Department of Global Medical Affairs, Alexion, AstraZeneca Rare Disease, Boston, MA 02210, USA

    1 shared publication
  • Javier de Las Heras

    Congenital Metabolic Disorders and Metabolic Liver Disease Laboratory, Biobizkaia Health Research Institute, 48093 Barakaldo, Spain; Division of Paediatric Metabolism, CIBERER, MetabERN, Cruces University Hospital, 48093 Barakaldo, Spain; Department of Paediatrics, University of the Basque Country (UPV/EHU), 48940 Leioa, Spain; AECOM Asociación Española para el Estudio de los Errores Congénitos del Metabolismo, Spain

    1 shared publication
  • Laura Frank

    Department of Metabolics, Alexion, AstraZeneca Rare Disease, Boston, MA 02210, USA

    1 shared publication

Latest Publications

  • Open Access

    Best Practices for the Nutritional Management of Infantile-Onset Lysosomal Acid Lipase Deficiency: A Case-Based Discussion

    by Fiona J. White, Javier de Las Heras, Celia Rodríguez-Borjabad, Simon A. Jones, Alexander Y. Kim, Jenna Moore, Florian Abel, Laura Frank, Rosie Jones, Suresh Vijay

    Infantile-onset lysosomal acid lipase deficiency (LAL-D) (Wolman disease, historically) is a rare inherited, rapidly progressive disorder caused by pathogenic variants in the LIPA gene, which encodes the enzyme LAL. LAL is essential for the metabolism of cholesteryl esters and triglycerides. LAL deficiency leads to the accumulation of cholesteryl esters and triglycerides within the lysosomes, macrophages, and parenchymal cells in most tissue types, including those in the liver, gastrointestinal tract, and lymph nodes but excluding the central nervous system. Infants with rapidly progressive LAL-D present with gastrointestinal disturbance, adrenomegaly with calcification, hepatosplenomegaly, growth failure due to malabsorption, and systemic inflammation. If untreated, rapidly progressive LAL-D typically leads to death within the first year of life. Treatment takes the two-pronged approach of sebelipase alfa, a human lysosomal acid lipase enzyme replacement therapy (ERT) that improves lipid metabolism, combined with nutritional management. Dietary substrate (lipid) reduction, known as substrate reduction therapy, is essential for optimal management in LAL-D. Following a nutritional plan and managing gastrointestinal disturbances together reduce systemic inflammation and improve growth, gut function, liver health, quality of life, and survival in patients with infantile-onset LAL-D. A multidisciplinary specialized team is necessary to manage the highly complex, multisystemic conditions in these patients. Nutritional management of LAL-D has evolved with increasing experience with the clinical management of ERT-treated infantile-onset LAL-D. A review of guidance for best practice nutritional management is needed. This narrative review aims to provide updated recommendations and guidance for the optimal nutritional management of infantile-onset LAL-D.